Change - Announcement of Appointment::Re-designation of Chief Commercial Officer to Chief Operating Officer
Issuer & Securities
CLEARBRIDGE HEALTH LIMITED
CLEARBRIDGE HEALTH LIMITED - SG1EB6000000 - 1H3
Change - Announcement of Appointment
Date &Time of Broadcast
Announcement Sub Title
Re-designation of Chief Commercial Officer to Chief Operating Officer
Submitted By (Co./ Ind. Name)
Non-Executive Non-Independent Chairman
Description (Please provide a detailed description of the event in the box below)
Re-designation of Chief Commercial Officer to Chief Operating Officer.
Date Of Appointment
Name Of Person
Liau Yen San, Jonathan
Country Of Principal Residence
The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)
The board of directors of the Company, having reviewed and considered Mr Liau's qualifications and experience, concurred with the recommendation of the nominating committee of the Company and approved the re-designation of Mr Liau as Chief Operating Officer.
Whether appointment is executive, and if so, the area of responsibility
Responsible for overseeing commercial strategy, new products/services initiatives and general development and management responsibilities of the Group with a view to strategise, streamline and improve operating performance.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Operating Officer
1) Master of Biochemical Engineering (Bioprocess Management), University College London, UK
2) Master of Business Administration, University of Chicago, US
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Conflict of interests (including any competing business)
Working experience and occupation(s) during the past 10 years
August 2017 - Present
Clearbridge Health Limited - Chief Commercial Officer
June 2016 - August 2017
EDBI Pte Ltd - Vice President, Investment
July 2013 - June 2016
Cordlife Group Limited ("Cordlife") - Senior Director, Corporate Development
November 2004 - June 2013
Cordlife Services (S) Pte Ltd (now known as Life Corporation Services (S) Pte Ltd) - Chief Operating Officer
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Shareholding interest in the listed issuer and its subsidiaries?
Mr Liau holds 5,019,760 ordinary shares (approximately 0.82%) in the Company. In addition, Mr Liau subscribed S$200,000 convertible bonds issued by the Company in March 2019.
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
1) Clearbridge USA Inc.
2) Biomedics Laboratory Pte. Ltd.
3) Clearbridge Biomedics Pte. Ltd.
4) Cordlife Sciences (India) Pvt. Ltd.
5) Cordlife Technologies Pte. Ltd.
6) CS Cell Technologies Pte. Ltd.
7) Cordlife Stem Cell Technology Limited
8) Cordlife Medical Phils., Inc.
9) Stemlife Berhad
10) PT. Cordlife Persada
1) Clearbridge Dental Holdings Pte. Ltd.
2) SAM Laboratory Pte. Ltd.
3) Clearbridge BSA Pte. Ltd.
4) Cleabridge Biophotonics, Inc.
5) Cleabridge Biophotonics FPM, Inc.
6) Clearbridge Health (Philippines) Inc.
7) Clearbridge Medical (Philippines) Inc. (fka Marzan Health Care Inc.)
8) Urban Dental (SG) Pte. Ltd.
9) LKDS (Hougang Green) Pte. Ltd.
10) LKDS (Yishun) Pte. Ltd.
11) LKDS (Simei) Pte. Ltd.
12) Dental Focus (Bendemeer) Pte. Ltd.
13) Dental Town (AMK) Pte. Ltd.
14) Dental Focus (Pioneer) Pte. Ltd.
15) DentalFamily (Pioneer) Pte. Ltd.
16) Dental Focus (People's Park) Pte. Ltd.
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
(c) Whether there is any unsatisfied judgment against him?
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
If Yes, Please provide full details
From the period of June 2014 to June 2015 when Mr Liau was the Senior Director of Corporate Development of Cordlife Group Limited. In June 2014, the Competition Commission of Singapore ("CCS") commenced an investigation on Cordlife in relation to its exclusive agreements with baby fair organisers and hospitals that potentially have the effect of limiting competition from other providers of cord blood bank services in Singapore. If these exclusive agreements were found to restrict competition in the cord blood bank industry, Cordlife would have infringed section 47 of the Competition Act (the prohibition against an abuse of a dominant position). Please refer to the link for further information: https://www.cccs.gov.sg/media-and-consultation/newsroom/media-releases/cordlife-removes-exclusive-arrangements.
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
If Yes, Please provide full details
Please refer to j(i). Mr Liau was involved in putting the relevant information together and representing the company in settlement discussion with CCS.
Any prior experience as a director of an issuer listed on the Exchange?
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)